Slingshot members are tracking this event:
MolecularMD Has Obtained CE Marking of a Diagnostic Assay Developed for a Daiichi Sankyo Phase II Clinical Trial
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Apr 25, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Ce Mark, Phase Ii